Engineers Gate Manager LP Has $613,000 Stake in Astrazeneca Plc $AZN

Key Points

• Engineers Gate Manager LP cut its AstraZeneca stake by 65.2% in the second quarter, selling 6,072 shares and retaining 3,235 shares worth approximately $613,000.
• AstraZeneca reported quarterly EPS of $2.63, ahead of the $2.50 consensus estimate, while revenue rose 6.4% year over year to $15.38 billion, slightly below expectations.
• The company received several positive regulatory developments for Enhertu, Klygefa, and Efzimfotase alfa. Analysts maintain a “Moderate Buy” consensus with an average price target of $206.67, despite some recent downgrades.

Engineers Gate Manager LP reduced its holdings in Astrazeneca Plc (NYSE:AZN - Free Report) by 65.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,235 shares of the company's stock after selling 6,072 shares during the quarter. Engineers Gate Manager LP's holdings in Astrazeneca were worth $613,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Kestra Investment Management LLC increased its holdings in shares of Astrazeneca by 1.9% in the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company's stock valued at $595,000 after purchasing an additional 63 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Astrazeneca by 51.8% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 258 shares of the company's stock valued at $50,000 after acquiring an additional 88 shares during the period. PFG Private Wealth Management LLC boosted its holdings in Astrazeneca by 5.5% in the second quarter. PFG Private Wealth Management LLC now owns 1,770 shares of the company's stock valued at $336,000 after acquiring an additional 92 shares during the last quarter. Spinnaker Investment Group LLC increased its position in Astrazeneca by 3.8% in the second quarter. Spinnaker Investment Group LLC now owns 2,899 shares of the company's stock worth $550,000 after purchasing an additional 106 shares during the period. Finally, Syon Capital LLC grew its position in shares of Astrazeneca by 0.9% during the 2nd quarter. Syon Capital LLC now owns 12,068 shares of the company's stock worth $2,288,000 after buying an additional 110 shares during the period. Institutional investors own 20.35% of the company's stock.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $168.29 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. The stock has a 50 day moving average price of $164.11 and a 200 day moving average price of $179.89. The stock has a market capitalization of $261.00 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Astrazeneca Plc has a 52 week low of $145.79 and a 52 week high of $212.71.

Astrazeneca (NYSE:AZN - Get Free Report) last released its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The company had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same quarter in the prior year, the firm posted $2.17 EPS. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. Analysts predict that Astrazeneca Plc will post 9.37 earnings per share for the current fiscal year.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Enhertu receives NHS funding recommendation in England. AstraZeneca and Daiichi Sankyo’s breast-cancer drug Enhertu was cleared for NHS use in England for patients with HER2-low metastatic breast cancer. The decision reverses an earlier cost-effectiveness rejection and could expand access and revenue in a significant European market. AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
• Positive Sentiment: Positive EU opinions advance two medicines. The European Medicines Agency’s CHMP recommended Enhertu for approval and backed Klygefa for AChR-positive generalized myasthenia gravis. Klygefa offers a once-weekly treatment option and was supported by Phase III data. Final European Commission approvals would broaden AstraZeneca’s commercial opportunities. AstraZeneca’s Enhertu and Klygefa Get Positive CHMP Opinions
• Positive Sentiment: FDA grants priority review to Efzimfotase alfa. The FDA’s priority review designation for the hypophosphatasia treatment could accelerate the regulatory process and improve visibility around a potential rare-disease growth driver. FDA Grants Priority Review to AstraZeneca’s Efzimfotase Alfa
• Positive Sentiment: Analyst raises medium-term EPS forecasts. Erste Group Bank lifted its FY2026 EPS estimate to $10.34 from $10.17 and its FY2027 forecast to $11.50 from $11.44. Both estimates exceed the current-year consensus of $9.34, signaling confidence in AstraZeneca’s earnings growth. AstraZeneca analyst estimates

Analyst Ratings Changes

AZN has been the subject of a number of analyst reports. HSBC lowered shares of Astrazeneca from a "buy" rating to a "hold" rating in a report on Monday, July 13th. Zacks Research downgraded Astrazeneca from a "hold" rating to a "strong sell" rating in a report on Monday, September 14th. Deutsche Bank Aktiengesellschaft raised Astrazeneca from a "sell" rating to a "hold" rating in a research note on Tuesday, September 15th. The Goldman Sachs Group restated a "buy" rating on shares of Astrazeneca in a report on Wednesday, July 1st. Finally, Weiss Ratings lowered shares of Astrazeneca from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, July 28th. Fourteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $206.67.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company's portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.